Armistice Capital’s KalVista Pharmaceuticals KALV Stock Holding History

Armistice Capital’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,236,000	Closed	-$24.9M	–	376
2026 Q1	$24.9M	Buy	1,236,000 +436,000	+55%	+$7.03M	0.44%	41
2025 Q4	$12.9M	Buy	+800,000	New	+$10.6M	0.15%	91

Other funds holding KALV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Armistice Capital's KALV Position: Q2 2026 in Review

Armistice Capital sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 1,236,000 shares — an estimated $24.9M sold.

Armistice Capital first reported a position in KALV in Q4 2025 and held it in 2 quarters. The position peaked at $24.9M in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

Armistice Capital reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Armistice Capital sold 1,236,000 KalVista Pharmaceuticals shares in Q2 2026, an estimated $24.9M.
Armistice Capital first reported a position in KalVista Pharmaceuticals in Q4 2025 and held it in 2 quarters.
Armistice Capital's KalVista Pharmaceuticals position peaked at $24.9M in Q1 2026.
1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.